Mesoblast

November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

August 14, 2018

Most valuable unpartnered assets reveal a changing of the guard

Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.

December 18, 2017

Tigenix draws closer to European nod

November 24, 2017

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

August 22, 2017

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?

August 11, 2017

Snippet roundup: A small success for Galapagos and a big one for Karius

June 14, 2016

The Mesoblast dream is over

May 17, 2016

Setbacks still outweigh successes in heart failure

May 17, 2016

Setbacks still outweigh successes in heart failure

March 11, 2016

Pivotal data overshadows Vericel’s heart failure win

November 03, 2015

Therapeutic focus – The Entresto Effect drives heart failure activity

Load More